Cancer vaccines' efficacy to stimulate T cell responses in patients is currently sub-optimal, and this can be potentially overcome by the delivery of antigens directly to antigen-presenting cells (APCs). To achieve this, single domain antibodies (nanobodies, Nbs) specific for receptors on APCs can be conjugated to liposomes to deliver cancer antigens. Here, we generated three CD169-specific Nb liposomes containing 3 different Nb clones (1B5, 1C1, and 2C2) and one CLEC9A-specific Nb liposome. Blocking experiments with CD169-specific antibodies indicated distinct binding epitopes on CD169 for 2C2 compared with 1B5 and 1C1. Both 2C2 and 1C1 Nb liposomes showed stronger binding and uptake by CD169-overexpressing cell lines and monocyte derived dendritic cells compared to 1B5 liposomes. Analysis of primary blood-derived APCs demonstrated strong uptake of 2C2 and 1C1 Nb liposomes by Axl+ Siglec-6+ DCs, classical monocytes, and DC3s, whereas CLEC9A-specific Nb liposomes were taken up by CLEC9A-expressing XCR1+ DC1s. In contrast, when gp100-specific T cell activation was evaluated using gp100-containing CD169-specific Nb liposomes and moDCs, only 1B5 Nb liposomes led to an enhanced T cell response. Using enriched blood DCs, we also observed an increased T cell activation by gp100-containing CLEC9A-specific Nb liposomes. To conclude, CD169- and CLEC9A-specific Nb liposomes are specifically taken up by primary CD169- or CLEC9A-expressing human APCs, and, depending on the Nb, can lead to a higher T cell activation. These results highlight the potential of Nb liposomes to improve vaccination strategies for immunotherapy.